Cargando…
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764628/ https://www.ncbi.nlm.nih.gov/pubmed/26820652 http://dx.doi.org/10.1007/s10549-016-3690-6 |
_version_ | 1782417406286626816 |
---|---|
author | Viale, Giuseppe Slaets, Leen de Snoo, Femke A. Bogaerts, Jan Russo, Leila van’t Veer, Laura Rutgers, Emiel J. T. Piccart-Gebhart, Martine J. Stork-Sloots, Lisette Dell’Orto, Patrizia Glas, Annuska M. Cardoso, Fatima |
author_facet | Viale, Giuseppe Slaets, Leen de Snoo, Femke A. Bogaerts, Jan Russo, Leila van’t Veer, Laura Rutgers, Emiel J. T. Piccart-Gebhart, Martine J. Stork-Sloots, Lisette Dell’Orto, Patrizia Glas, Annuska M. Cardoso, Fatima |
author_sort | Viale, Giuseppe |
collection | PubMed |
description | Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the correlation of central IHC/FISH assessments with microarray mRNA readouts of ER, PgR, and HER-2 status in the MINDACT trial and to determine if any discordance could be attributed to intratumoral heterogeneity or the DCIS and normal tissue components in the specimens. MINDACT is an international, prospective, randomized, phase III trial investigating the clinical utility of MammaPrint in selecting patients with early breast cancer for adjuvant chemotherapy (n = 6694 patients). Gene-expression data were obtained by TargetPrint; IHC and/or FISH were assessed centrally (n = 5788; 86 %). Macroscopic and microscopic evaluation of centrally submitted FFPE blocks identified 1427 cases for which the very same sample was submitted for gene-expression analysis. TargetPrint ER had a positive agreement of 98 %, and a negative agreement of 95 % with central pathology. Corresponding figures for PgR were 85 and 94 % and for HER-2 72 and 99 %. Agreement of mRNA versus central protein was not different when the same or a different portion of the tumor tissue was analyzed or when DCIS and/or normal tissue was included in the sample subjected to mRNA assays. This is the first large analysis to assess the discordance rate between protein and mRNA analysis of breast cancer markers, and to look into intratumoral heterogeneity, DCIS, or normal tissue components as a potential cause of discordance. The observed difference between mRNA and protein assessment for PgR and HER-2 needs further research; the present analysis does not support intratumoral heterogeneity or the DCIS and normal tissue components being likely causes of the discordance. |
format | Online Article Text |
id | pubmed-4764628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-47646282016-03-04 Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance Viale, Giuseppe Slaets, Leen de Snoo, Femke A. Bogaerts, Jan Russo, Leila van’t Veer, Laura Rutgers, Emiel J. T. Piccart-Gebhart, Martine J. Stork-Sloots, Lisette Dell’Orto, Patrizia Glas, Annuska M. Cardoso, Fatima Breast Cancer Res Treat Clinical Trial Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the correlation of central IHC/FISH assessments with microarray mRNA readouts of ER, PgR, and HER-2 status in the MINDACT trial and to determine if any discordance could be attributed to intratumoral heterogeneity or the DCIS and normal tissue components in the specimens. MINDACT is an international, prospective, randomized, phase III trial investigating the clinical utility of MammaPrint in selecting patients with early breast cancer for adjuvant chemotherapy (n = 6694 patients). Gene-expression data were obtained by TargetPrint; IHC and/or FISH were assessed centrally (n = 5788; 86 %). Macroscopic and microscopic evaluation of centrally submitted FFPE blocks identified 1427 cases for which the very same sample was submitted for gene-expression analysis. TargetPrint ER had a positive agreement of 98 %, and a negative agreement of 95 % with central pathology. Corresponding figures for PgR were 85 and 94 % and for HER-2 72 and 99 %. Agreement of mRNA versus central protein was not different when the same or a different portion of the tumor tissue was analyzed or when DCIS and/or normal tissue was included in the sample subjected to mRNA assays. This is the first large analysis to assess the discordance rate between protein and mRNA analysis of breast cancer markers, and to look into intratumoral heterogeneity, DCIS, or normal tissue components as a potential cause of discordance. The observed difference between mRNA and protein assessment for PgR and HER-2 needs further research; the present analysis does not support intratumoral heterogeneity or the DCIS and normal tissue components being likely causes of the discordance. Springer US 2016-01-28 2016 /pmc/articles/PMC4764628/ /pubmed/26820652 http://dx.doi.org/10.1007/s10549-016-3690-6 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Viale, Giuseppe Slaets, Leen de Snoo, Femke A. Bogaerts, Jan Russo, Leila van’t Veer, Laura Rutgers, Emiel J. T. Piccart-Gebhart, Martine J. Stork-Sloots, Lisette Dell’Orto, Patrizia Glas, Annuska M. Cardoso, Fatima Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title_full | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title_fullStr | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title_full_unstemmed | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title_short | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance |
title_sort | discordant assessment of tumor biomarkers by histopathological and molecular assays in the eortc randomized controlled 10041/big 03-04 mindact trial breast cancer: intratumoral heterogeneity and dcis or normal tissue components are unlikely to be the cause of discordance |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764628/ https://www.ncbi.nlm.nih.gov/pubmed/26820652 http://dx.doi.org/10.1007/s10549-016-3690-6 |
work_keys_str_mv | AT vialegiuseppe discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT slaetsleen discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT desnoofemkea discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT bogaertsjan discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT russoleila discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT vantveerlaura discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT rutgersemieljt discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT piccartgebhartmartinej discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT storkslootslisette discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT dellortopatrizia discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT glasannuskam discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance AT cardosofatima discordantassessmentoftumorbiomarkersbyhistopathologicalandmolecularassaysintheeortcrandomizedcontrolled10041big0304mindacttrialbreastcancerintratumoralheterogeneityanddcisornormaltissuecomponentsareunlikelytobethecauseofdiscordance |